Latest News & Features
Americas
Drugmaker Genus Lifesciences and pharmaceutical company Mallinckrodt have agreed to settle their trade secret dispute related to a cocaine hydrochloride formulation. 28 June 2022
Big Pharma
India-based Dr Reddy’s has ended its litigation with Indivior and Aquestive Therapeutics over a generic version of opioid addiction treatment Suboxone sublingual film. 27 June 2022
Big Pharma
The director of the US Patent and Trademark Office, Kathi Vidal, has unveiled long-anticipated guidance for the procedures governing the discretionary denials that can be handed down by the US Patent Trial and Appeal Board (PTAB) when declining to review a patent’s validity. 23 June 2022
Big Pharma
The US Court of Appeals for the Federal Circuit has held that a patent covering Novartis’ multiple sclerosis drug Gilenya is invalid, potentially opening the floodgates for the introduction of generic versions of the drug. 23 June 2022
Big Pharma
The European Commission has opened an antitrust investigation to assess whether Switzerland-headquartered Vifor Pharma has engaged in anticompetitive conduct. 21 June 2022
Medtech
Ohio-based Cleveland Medical Devices (CleveMed) has accused ResMed of infringing patents through the sale of devices and software for the testing and treatment of sleep-disordered breathing or apnea. 21 June 2022
Big Pharma
Biotech company Glycosyn has sued Abbott Laboratories for allegedly infringing its patented method for manufacturing a key ingredient in infant formula milk, found in three of Abbott’s infant formula products under the Similac brand. 16 June 2022
Big Pharma
Zydus Pharmaceuticals has attempted to revive an antitrust lawsuit accusing Takeda Pharmaceuticals of attempting to delay generic competition and of abusing its dominant market position. 16 June 2022
article
In the US, the impact of authorised biologics on biosimilars is post-regulated by the competition authorities, while in Europe, pharmaceutical regulatory authorities consider competition impacts in addition to post-regulation by the competition authorities. 16 June 2022
Big Pharma
BMS unit Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have urged the US Supreme Court to reinstate their $1.2 billion win in a patent clash with Kite Pharma, a subsidiary of Gilead. 16 June 2022